Updated agreement reinforces staged pricing cuts for new generic drugs
Most patients relapse within five years, and Bausch Health’s PrOKEDI targets that risk
Generic rollout carries fine print that plan sponsors need to understand, says Canada Life’s Barb Martinez
Guidelines still advise stopping GLP-1 drugs one to two months before pregnancy
US employers retreat from GLP-1 coverage just as a stronger obesity treatment arrives
Analysts warn side effects could sink the treatment's commercial future, despite liver gains
